Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

16.79 -0.15 (-0.89%)
Streaming Delayed Price Updated: 2:42 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year ↗
Via Stocktwits
News headline image
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗
Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S. 
Via Stocktwits
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Examining the Future: KalVista Pharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Posts 154% Expense Jump in Q1 ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.